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Background: The aims of this analysis were to investigate features and outcome of high-grade osteosarcomas of the
mobile spine.
Patients and methods: Since 1977, 20 Cooperative Osteosarcoma Study Group patients had a diagnosis of
high-grade osteosarcomas of the mobile spine and were included in this retrospective analysis of patient-, tumor- and
treatment-related variables and outcome.
Results: The median age was 29 years (range 5–58). Most frequent tumor sites were thoracic and lumbar spine. All
but three patients had nonmetastatic disease at diagnosis. Treatment included surgery and chemotherapy for all
patients, 13 were also irradiated. Eight patients failed to achieve a macroscopically complete surgical remission (ﬁve
local, one primary metastases, two both), six died, two are alive, both with radiotherapy. Of 12 patients with complete
remission at all sites, three had a recurrence (two local, one metastases) and died. The median follow-up of the
11 survivors was 8.7 years (range 3.1–22.3), 5-year overall and event-free survival rates were 60% and 43%. Age <40
years, nonmetastatic disease at diagnosis and complete remission predicted for better overall survival (OS, P < 0.05).
Conclusions: Osteosarcomas of the mobile spine are rare. With complete resection (and potentially radiotherapy) and
chemotherapy, prognosis may be comparable with that of appendicular osteosarcomas.
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introduction
Vertebral osteosarcomas are rare accounting for only 1%–4% of
all osteosarcomas [1–4] and 5%–23% of all primary malignant
osseous spinal neoplasms [3, 5–7]. Early studies reported a poor
prognosis, and treatment was limited [1, 3, 8, 9]. Today en bloc
resection and chemotherapy are recommended [10], the role of
radiotherapy remains unclear. Recent studies still observed
limited long-time survival [5, 11, 12].
The purpose of this study was to analyze the patient-,
tumor- and treatment-related variables and outcomes of
patients with primary osteosarcoma of the mobile spine treated
according to contemporary osteosarcoma regimens.
materials and methods
In January 2011, the interdisciplinary Cooperative Osteosarcoma Study
Group (COSS) had registered 3865 patients with osteosarcoma, and treated
in consecutive COSS trials since 1977. All studies were accepted by the
appropriate ethics and Protocol Review Committees, respectively. An
informed consent was required from all patients or their legal guardians.
For this retrospective study, we searched the COSS database for patients
with histologically proven high-grade osteosarcoma of the mobile spine.
The mobile spine was deﬁned as cervical, thoracic and lumbar spine.
Patients with involvement of the ileum or sacrum were excluded, as were
those with low-grade tumors. The ﬁrst author reviewed all information
contained in the COSS database and in the patient ﬁles. In the case of
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incomplete information, the contributing centers were requested to provide
the missing data.
Evaluation procedures used to deﬁne the extension of the primary
tumor included conventional radiography in all studies, whereas other
methods [computed tomography (CT) scans and magnetic resonance
imaging (MRIs)] varied with time and availability. Requirements for
exclusion of primary metastases were a negative chest X-ray and a negative
bone scan. As of 1991, CT scanning of the chest was also mandatory.
During follow-up, radiograms of the chest and the primary tumor were to
be repeated at regular intervals speciﬁed in the respective protocols.
All patients with high-grade tumors were to be treated according to the
same guidelines as patients with extremity tumors with surgery and
multidrug chemotherapy. Chemotherapy was carried out following the
COSS protocols for high-grade osteosarcomas [13]. After the ﬁrst trial
COSS-77, which was based on postoperative, adjuvant therapy only,
all COSS regimens included a uniform treatment concept of preoperative,
neoadjuvant chemotherapy followed by surgery of the primary tumor and
adjuvant chemotherapy. Details have been reported previously [14–18].
The aim of surgical intervention was complete resection of all tumor
manifestations. A complete surgical remission was assumed only when all
detectable tumor foci were removed macroscopically complete during ﬁrst-
line therapy. This was assessed separately for local and metastatic disease.
A total complete remission was only assumed if a macroscopically
complete surgical remission of all tumor sites had been achieved. Response
to chemotherapy was assessed histologically according to Salzer-Kuntschik
et al. [19]. The distinction between good and poor responses was set at
10% residual viable tumor.
Statistics were calculated using IBM SPSS Statistics software version 20.0
(IBM, Armonk, NY). Overall survival (OS) and event-free survival (EFS)
were calculated using the Kaplan–Meier method [20]. The log-rank test
was used to compare differences between the survival curves [21]. OS was
calculated from the date of diagnostic biopsy until death from any cause
and EFS until relapse or death, whichever occurred ﬁrst. Patients who
never achieved a complete surgical remission were supposed to have
suffered an event on the ﬁrst day after biopsy or primary operation if no
biopsy was done.
results
Thirty high-grade osteosarcomas involving the mobile spine
were identiﬁed among 3865 registered patients (0.8%). Ten of
these had to be excluded from this analysis: nine had
involvement of the sacrum and/or ileum, no sufﬁcient
information was available for one. Altogether, 20 patients from
16 institutions in Germany (14), Austria (1) and Switzerland
(1), diagnosed in the year 1988–2009, were eligible for this
retrospective investigation. Five patients have previously been
reported as part of an analysis of osteosarcomas of the spine
including the sacrum [22].
In 15 of 20 eligible patients, the histological diagnosis was
conﬁrmed by a member of the COSS-reference-pathology-
panel. In three patients, local pathologists made the diagnosis,
but no material was available for a reference opinion. In two
individuals, local pathologists had diagnosed a soft-tissue-
sarcoma and a not-otherwise-speciﬁed-sarcoma, respectively,
but this was revised by a reference review.
Nine patients were female, and 11 eleven male. The median
age at diagnosis was 29 years (mean 31, range 5–58), 14 were
<40 years. No patient had had prior radiotherapy or suffered
from Paget’s disease. One osteosarcoma occurred as a second
malignancy following surgically treated urothelial cell
carcinoma of the bladder. This patient later went on to develop
a third malignancy during osteosarcom therapy, namely
papillary carcinoma of the thyroid, which was removed
completely.
Information about pain at diagnosis was available for 19 of
20 patients, all of whom presented with pain (median duration:
85 days). Data on neurological dysfunction was available for all
patients and it was experienced by nine (median duration:
11 days). A pathologic fracture was recognized in three
patients.
Primary tumor sites were cervical (n = 1), cervico-thoracic
(n = 1), thoracic (n = 9) and lumbar (n = 9) spine. The most
frequent subtypes were osteoblastic (n = 10) and telangiectatic
(n = 4) osteosarcoma (Table 1). Tumor volume could be
estimated for six patients (median: 120 cm³, range 3–576).
Three patients had metastases at diagnosis, all to the lungs and
one additionally to distant bones and liver.
All patients underwent resection of their primary tumor,
fourteen as primary resection, four following preoperative
chemotherapy, one after preoperative chemo- and radiotherapy
and one following preoperative radiotherapy alone. The
median number of surgical procedures prior to best remission
was 2 (range 1–3). Eight patients failed to achieve a total,
macroscopically complete surgical remission (ﬁve local, one
metastases, two both). Local complete macroscopic resection
was achieved in 13 individuals, one with residual primary
metastases. Local therapy included radiotherapy of thirteen
primary tumors, 6 of which were removed incompletely and 7
completely. Median radiation dose was 50 Gy (range: 35–66).
Information about radiation-associated acute side effects was
obtained for in all 13 irradiated individuals, no toxicities >2
CTCAE v3 were reported.
Systemic treatment included chemotherapy with cisplatin
(n = 20), doxorubicin (n = 20), ifosfamide (n = 19) and
methotrexate (n = 16). Five patients received carboplatin and/or
etoposide during primary therapy, too. Gemcitabine was used
in one patient due to progressive disease. With the tentative
diagnosis of a soft-tissue-sarcoma, one patient received three
courses of vincristine and actinomycin D
Preoperative chemotherapy was used in 5 of 20 patients.
Information on response was available for four of them, three
had a poor (two grade 4, one grade 6) and one a good
response (grade 1).
Of 12 patients with complete remission at all sites,
3 experienced recurrent disease, all within 5 years of diagnosis
(2 local, 1 bone metastases) and died. The two patients with
local relapse had not received radiotherapy during primary
treatment. Of the 5 patients with incomplete surgery of the
primary as only cause of residual tumor, 3 died (2 with and
one without radiotherapy) and 2 are still alive, 10.0 and
14.2 years after diagnosis, both following radiotherapy.
In April 2012, after a median follow-up of 3.8 years (range
0.7–22.3) for all patients and 8.7 years (range 3.1–22.3) for the
survivors, 11 of 20 patients were still alive, nine in ﬁrst
complete surgical remission and two without progression
following incomplete surgery and deﬁnitive radiotherapy.
Among the nine deceased patients, ﬁve died of progressive
disease without ever having achieved a remission, three of
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Table 1. Patient characteristics, treatment and outcomes
No. Gender Age
(years)
Vertebrae
body
Subtype Primary
metastases
Total complete
surgical macroscopic
remission
Radiotherapy
(Gy)
DDP DOX IFO MTX Other
drugs
First event
(years from
diagnosis)
Status and follow-
up (years from
diagnosis)
1 F 30 T 10–11 Telangiectatic None Yes + (47) + + + + Metastatic
relapse (4.2)
DOD in FR (7.1)
2 M 19 T 1–3 Osteoblastic None Yes − + + + + None NED (10.0)
3 F 5 C 4 Telangiectatic None No (local) + (50) + + + + Carbo,
Eto
No CR (local) NED (14.2)
4 F 19 T 8–10 Chondroblastic None Yes − + + + + Local relapse
(2.5)
DOD in FR (3.0)
5 M 11 C 7–T2 Osteoblastic None Yes + (45) + + + + None NED (7.2)
6 M 47 L 5 Small cell None No (local) + (54) + + + + Carbo,
Eto
No CR (local) DOD in PD (2.8)
7 M 20 T 10 Osteoblastic None No (local) + (45) + + + + Eto.
VCR,
ActoD
No CR (local) DOD in PD (0.7)
8 M 38 T 6 Osteoblastic None Yes + (49) + + + + None NED (6.8)
9 F 39 L 3 Unclassiﬁed None Yes + (56) + + − + None NED (2.5)
10 M 50 L 2 Osteosarcoma
resembling
osteoblastoma
None No (local) − + + + + Carbo,
GEM
No CR (local) DOD in PD (1.2)
11 M 36 L 5 Unclassiﬁed None Yes + (66) + + + + None NED (3.9)
12 F 58 L 5 Osteoblastic PUL No (local, PUL) + (60) + + + − No CR (local
and mets)
DOD in PD (1.0)
13 F 50 L 5 Osteoblastic None Yes − + + + − Local relapse
(2.7)
DOD in FR (2.8)
14 M 16 T 1–2 Chondroblastoma-
like
PUL No (PUL) − + + + + No CR (mets) DOC in PD (1.9)
15 M 16 L 2 Telangiectatic None Yes − + + + + None NED (22.3)
16 F 11 T 5–6 Osteoblastic None Yes + (56) + + + + None NED (3.1)
17 F 18 T 4 Osteoblastic None No (local) + (45) + + + + No CR (local) NED (10.0)
18 F 52 L 1 Osteoblastic PUL, OSS,
HEP
No (local, PUL, OSS,
HEP)
+ (>35) + + + − Carbo,
Eto
No CR (local
and mets)
DOD in PD (1.0)
19 F 57 L 4 Telangiectatic none Yes + (56) + + + − None NED (2.2)
20 F 28 T 9 Osteoblastic none Yes − + + + + None NED (15.3)
F, female; M, male; C, cervical spinal segment; T, thoracic spinal segment; L, lumbar spinal segment; PUL, pulmonal; OSS, osseous; HEP, hepatic; Gy, Gray; DDP, cisplatin; DOX, doxorubicin; IFO, ifosfamide;
MTX, methotrexate; Carbo, carboplatin; Eto, etoposid; VCR, vincristin; ActoD, actinomycinD; GEM, gemcitabine; CR, complete remission; mets, metastases; NED, no evidence of disease; DOD, dead of
disease; DOC, dead of complications; PD, primary disease; FR, ﬁrst relapse.
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recurrence following remission and one due to sepsis during
primary therapy.
Actuarial EFS and OS-rates were 43% and 60% after 5 years
and 43% and 53% after 10 years, respectively (Figure 1). Age
40 years, primary nonmetastatic disease and local and total
complete surgical remission predicted for better OS (P < 0.05)
and all with the exception of age younger than 40 years also
for better EFS (P < 0.05) (supplementary Table S1, available at
Annals of Oncology online). In our cohort, irradiated patients
had a 5- and 10-year OS of 69% and 55% and patients without
radiotherapy had 43% after 5 and 10 years (P = 0.57).
discussion
Information about osteosarcoma of the mobile spine is very
limited. To our knowledge, only three series excluding pelvic
and sacral tumors have been published [1, 8, 11]. All of them
included fewer patients than our study.
Only 0.8% of our registered osteosarcomas were located in
the mobile spine, conﬁrming the rarity of this disease [1–4].
The median and mean age of patients in this series was
somewhat lower than previously reported in most other series
(35–52 years), reﬂecting the predominantly pediatric
constituency of the COSS group [1, 3–6, 9, 11, 12]. None of
our patients had a history of prior radiotherapy or Paget’s
disease. Other series of vertebral osteosarcoma in general have
reported up to 30%–40% and more of secondary
osteosarcomas [1, 3, 6, 7, 9, 12]. Like in other series, primaries
often involved the lumbar vertebrae [1, 3, 6, 7, 8, 9, 12], but a
similar proportion of tumors were located in the thoracic
spine. This is in accordance with Ilaslan et al. [4] (after
excluding the sacrum) and Schwab et al. [11]. Similar to
Schwab et al., our rate of metastatic disease at diagnosis was
around 15% [11]. Other authors have reported higher rates of
28%–62% [5, 12].
In the 1980s, three ‘early’ series of vertebral osteosarcoma
studied patients managed over a period of 60–80 years. The
rates of complete resections and the use of chemotherapy were
low. Radiation was mainly palliative [1, 3, 8]. In 1988,
Sundaresan et al. reported 24 patients with vertebral
osteosarcoma who were divided into two subgroups. The ﬁrst
encompassed 13 patients treated similar to the ‘early’ series
1949–1977. The remaining 11 patients, treated in the year
1978–1984, demonstrated a shift toward chemotherapy,
complete resection was now achieved in 7 and all but two were
irradiated, including completely resected tumors [9].
More recently, three other studies of spinal osteosarcoma
were published [5, 11, 12]. In 2010, data from the Surveillance,
Epidemiology and End Results Program of 430 vertebral
osteosarcomas, including those of the sacrum, were reviewed.
Surgical data were available for only 27% of patients of whom
62% underwent resection. Approximately one-third of all
primary tumors were irradiated. Data regarding chemotherapy
were not presented [5]. In a series from the Massachusetts
General Hospital which included 26 patients, treated in the
year 1982–2010, 20 underwent surgical procedures and
complete en bloc resection was achieved in 7. Radiotherapy
was carried out in all but two and multidrug chemotherapy
was given to all but one patient [12]. Schwab et al. published
17 patients with osteosarcoma of the mobile spine of whom all
received methotrexate- and doxorubicin-based chemotherapy.
All but two patients were treated surgically and en bloc
resection was achieved in nine. Eight of 17 patients were also
irradiated [11]. In summary over the years treatment of
vertebral osteosarcoma showed a tendency to increased use of
chemotherapy and more aggressive surgery with a higher rate
of complete resections and a frequent use of radiotherapy to
optimize local control. The patients included in our series were
treated similar to those of the other recent series.
The ‘early’ studies reported very poor survival data [1, 3, 8,
9]. The trend toward more aggressive therapy in more recent
series was associated with improved but still limited survival
with 5-year survival rates from 18% to 45 % [5, 11, 12]. The
only reported 10-year survival rate was 8% [5]. We observed
more encouraging long-term data: OS expectancies after 5 and
10 years were 60% and 53%, respectively.
While no analyses of prognostic factors were carried out in
the ‘early’ studies, recent analyses have hinted toward such
factors. Not surprisingly, we conﬁrmed that primary metastatic
disease has negative prognostic implications [5, 11, 23] that the
outcome of younger patients is better [23] and that the extent
to which a tumor and, if present, its metastases can be removed
is of utmost importance (supplementary Table S1, available at
Annals of Oncology online). The aim of surgery in
osteosarcoma in general should always be complete resection of
the tumor in an en bloc-approach and ideally with wide and
therefore negative margins [24]. Given the site-speciﬁc
anatomic constraints, appropriate resection margins, however,
are particularly difﬁcult to obtain in the mobile spine, and
trying to enforce such margins can be associated with
signiﬁcant morbidity [10]. Nevertheless, the well-known
relation between margins and local control could also be
conﬁrmed for spine sarcomas [25, 26]. The type of resection
chosen will impact upon the margins. The rate of local
recurrence after piecemeal resections has been shown to be
higher than after en bloc resections [25]. En bloc resections
provide improved local control [10, 25, 26]. It is still under
discussion if this translates into improved OS [11, 12]. Our
Figure 1. Overall (solid line) (OS) and event-free (dashed line) survival
(EFS) of 20 patients with high-grade osteosarcoma of the mobile spine.
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data support the impression that en bloc resection should be
recommended whenever feasible, as it provides improved local
control and probably improved OS [10].
Despite improvements in surgery, inadequate margins or
incomplete resections remain to pose a challenge in
osteosarcoma of the mobile spine. Radiation can help to
provide local control of osteosarcoma in situations with
microscopic or minimal residual disease [27]. In accordance
with recent recommendations [28], we suggest that
radiotherapy should be considered in cases of incomplete
resections or inadequate margins. Two of our patients with
macroscopically incomplete resection achieved permanent local
control following radiotherapy, but this ﬁnding should not be
misunderstood: the main goal of surgery remains a RO
resection with wide margins, not debulking surgery.
Our analysis has certain limitations: retrospectiveness,
selection bias, lack of a control group, small number of patients
treated during two decades and the limitation of surgical
analysis to macroscopic completeness of resection; neither type
of resection nor resection margins were evaluated.
Nevertheless, this is probably the most detailed analysis of
patient- and tumor-related variables and therapeutic measures
ever carried out for osteosarcoma of the mobile spine allowing
to identify clinical factors that might predict long-term
outcomes and to give recommendations for treatment. Despite
including no more than 20 patients, it is, to our knowledge,
also the largest analysis of this very rare tumor site.
Using intensive multimodal treatment, we achieved an
outcome which was surprisingly favorable. Treatment of this
disease remains challenging, but we believe that the results
achieved justify aggressive approaches. We recommend
treatment by surgery and multidrug chemotherapy according
to the same guidelines as for patients with extremity tumors,
and that radiotherapy should be added in cases with
incomplete or inadequate margins and should at least be
considered in all others. With such an aggressive approach,
prognosis may become comparable with that of osteosarcoma
of the extremities [29].
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